In the quarter under review the Company announced the completion of enrolment and interim results
from its phase II clinical trial of INV012 (nadolol) in smoking cessation. The interim results showed
clinically relevant changes in four biomarkers of inflammation in INV102 (nadolol) treated patients
compared to placebo.
Also during the quarter, the Company announced that it would raise approximately $5 million through
a placement to professional and sophisticated investors and a 2 for 7 non-renounceable rights issue
entitlement offer to existing eligible shareholders.
Subsequent to the end of the quarter, the Company announced that the entitlement offer was fully
subscribed with demand exceeding shares available. The Company also announced the completion
of a $1.3 million placement to partially satisfy the strong demand and reduce the amount of scaleback
required for the entitlement offer top-up facility, bringing the total capital raised to $6.3 million.
IVX Price at posting:
1.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)